5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥50% from the phase II portion of KRYSTAL-7

Marina Chiara Garassino, Willemijn S.M.E. Theelen, P.A. Jänne, Laurentine Boom, F. De Marinis, M. Dómine Gómez, Ernest Nadal, Luis Paz‐Ares, Weili Gu, E. Felip, David Hakimian, Fadi Kayali, J. Porter, Eric Schaefer, Lauren Jimenez‐Kurlander, Conor M. Lane, A. Sachdeva, Laura J. Eccles, A.I. Spira